Value of Epicardial Adipose Tissue Thickness in Predicting Major Adverse Cardiovascular Events in Patients with Coronary Artery Disease and Metabolic Syndrome

ORIGINAL ARTICLE
Andrey R. Kim, Rano B. Alieva, Aleksandr B. Shek, Shokhistakhon S. Akhmedova, Liliya E. Kan

 
For citation: Kim AR, Alieva RB, Shek AB, Akhmedova ShS, Kan LE. Value of Epicardial Adipose Tissue Thickness in Predicting Major Adverse Cardiovascular Events in Patients with Coronary Artery Disease and Metabolic Syndrome. International Journal of Biomedicine. 2025;15(1):58-63. doi:10.21103/Article15(1)_OA1
 
Originally published March 5, 2025

Abstract: 

Background: Currently, coronary artery disease (CAD) combined with cardiometabolic disorders and diabetes mellitus is one of the most common phenotypes of residual risk in cardiology. Epicardial adipose tissue (EAT) thickness attracts attention in CAD risk stratification as a significant integral marker of lipid metabolism disorders and insulin resistance. The aim of the study was to evaluate EAT thickness as an additional non-invasive criterion for diagnosis and risk stratification in patients with CAD and metabolic syndrome (MetS) in the Uzbek population.
Methods and Results: The study included 224 patients diagnosed with CAD, specifically those with functional class III angina pectoris and MetS. MetS criteria were defined in accordance with the IDF criteria (2005). Parameters assessed included biochemical markers of lipid and glucose metabolism, inflammatory markers, and imaging markers such as EAT thickness, carotid intima-media thickness, and carotid artery stenosis percentage. Major adverse cardiovascular events (MACE) during the 2-year follow-up included cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and recurrent hospitalizations due to destabilization requiring coronary angiography and revascularization.
All patients were divided into 2 groups: Group 1 (n=137) included 137 patients without MACE, and Group 2 included 87 patients who experienced MACE during the 2-year follow-up. Group 2 showed significantly higher age (P<0.05), prevalence of T2DM (P<0.05), history of coronary revascularization (P<0.05), body mass index (BMI) (P<0.01), waist circumference (WC) (P<0.05), hsCRP (P<0.05), EAT thickness (P<0.01), and lower levels of HDL-C (P=0.000). Among imaging markers, EAT thickness was significantly higher in Group 2 (P<0.01), contrasting with the IMT and the percentage of carotid artery stenosis, which did not show significant differences. The results showed the substantial predictive value of EAT thickness and age, followed by Lp(a) and BMI, in assessing the 2-year risk of MACE in patients with CAD and MetS. Using all four significant variables—EAT thickness, age, Lp(a), and BMI—a multiple logistic regression model was constructed, in which the odds ratios for the selected variables were 1.246, 1.054, 1.016, and 1.087, respectively.
Conclusion: EAT thickness measured by echocardiography is a valuable prognostic factor in the risk stratification of patients with CAD and MetS.

Keywords: 
coronary artery disease • metabolic syndrome • epicardial adipose tissue • major adverse cardiovascular events
References: 
  1. Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021 Jan 1;42(1):113-131. doi: 10.1093/eurheartj/ehaa099. PMID: 32176778.
  2. Drapkina OM, Shepel RN, Deeva TA. The thickness of the epicardial fat is the "visit card" of metabolic syndrome. Obesity and metabolism. 2018;15(2):29-34. (In Russ.) doi: 10.14341/omet9295
  3. Mustafina IA, Ionin VA, Dolganov AA, Ishmetov VSh, Pushkareva AE, Yagudin TA, Danilko KV, Zagidullin NSh. Role of epicardial adipose tissue in the development of cardiovascular diseases. Russian Journal of Cardiology. 2022;27(1S):4872. (In Russ.) doi:10.15829/1560-4071-2022-4872
  4. Nakanishi K, Fukuda S, Tanaka A, Otsuka K, Jissho S, Taguchi H, Yoshikawa J, Shimada K. Persistent epicardial adipose tissue accumulation is associated with coronary plaque vulnerability and future acute coronary syndrome in non-obese subjects with coronary artery disease. Atherosclerosis. 2014 Nov;237(1):353-60. doi: 10.1016/j.atherosclerosis.2014.09.015. Epub 2014 Sep 28. PMID: 25310459.
  5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006 May;23(5):469-80. doi: 10.1111/j.1464-5491.2006.01858.x. PMID: 16681555.
  6. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res. 2003 Feb;11(2):304-10. doi: 10.1038/oby.2003.45. PMID: 12582228.
  7. Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018 Feb;40(2):215-224. doi: 10.1007/s00281-017-0666-5. Epub 2017 Dec 5. PMID: 29209827; PMCID: PMC5809518.
  8. Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, Davis RJ. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2751-2760. doi: 10.1073/pnas.1920004117. Epub 2020 Jan 24. PMID: 31980524; PMCID: PMC7022151.
  9. Tesche C, Bauer MJ, Straube F, Rogowski S, Baumann S, Renker M, Fink N, Schoepf UJ, Hoffmann E, Ebersberger U. Association of epicardial adipose tissue with coronary CT angiography plaque parameters on cardiovascular outcome in patients with and without diabetes mellitus. Atherosclerosis. 2022 Dec;363:78-84. doi: 10.1016/j.atherosclerosis.2022.10.006. Epub 2022 Oct 17. PMID: 36280469.
  10. Sequeira DI, Ebert LC, Flach PM, Ruder TD, Thali MJ, Ampanozi G. The correlation of epicardial adipose tissue on postmortem CT with coronary artery stenosis as determined by autopsy. Forensic Sci Med Pathol. 2015 Jun;11(2):186-92. doi: 10.1007/s12024-015-9659-7. Epub 2015 Feb 25. PMID: 25711291.
  11. Douglass E, Greif S, Frishman WH. Epicardial Fat: Pathophysiology and Clinical Significance. Cardiol Rev. 2017 Sep/Oct;25(5):230-235. doi: 10.1097/CRD.0000000000000153. PMID: 28604567.

Download Article
Received January 1, 2025.
Accepted February 26, 2025.
©2025 International Medical Research and Development Corporation.